poisar

Stocks · News reference

Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process

Jul 15, 2026, 1:02 PMBenzinga Newsdesk

The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by approximately 400%,

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RGNT
Source
benzinga
Observed
Jul 15, 2026, 1:02 PM
Checked
Jul 15, 2026, 1:02 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Jul 20, 2026, 1:03 PMBenzinga Newsdesk

    Regentis Gets Japan Patent Office Notice of Allowance For Organic Solvent‑Free Protein‑Polymer Conjugate Compositions, Covering GelrinC Manufacturing Process And Ready‑to‑Use Liquid Formulation for Articular Cartilage Repair

    Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell

    Read original at benzinga
    RGNT